Molecular characterization of low grade and high grade bladder cancer

Alessandro Apollo, Valerio Ortenzi, Cristian Scatena, Katia Zavaglia, Paolo Aretini, Francesca Lessi, Sara Franceschi, Sara Tomei, Carlo Alberto Sepich, Paolo Viacava, Chiara Maria Mazzanti and Antonio Giuseppe Naccarato

PLOS ONE, 2019, vol. 14, issue 1, 1-17

Abstract: Background: Bladder cancer (BC) is the 9th most common cancer diagnosis worldwide. Low grade (LG) represents 70% of all BCs, characterized by recurrence and rare ability (10–15%) to progress to high grade (HG) and invade. The remaining 30% is high grade (HG), fast invasive BC, which is resistant to therapy. Identifying biomarkers for predicting those tumors able to progress is a key goal for patient outcome improvement. This study focuses on the most promising prognostic markers. Materials and methods: TP53 and FGFR3 mutational status, Survivin, CK19, CK20, E-cadherin and CD44 gene expression analysis were performed on 66 BCs. Results: Survivin was found associated to tumor grade (p

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0210635 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 10635&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0210635

DOI: 10.1371/journal.pone.0210635

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().